Creabilis, a late clinical stage European biotechnology company specializing in developing treatments in dermatology, inflammation and pain, has appointed Catherine Moukheibir to its board of directors.

Catherine has more than 30 years of experience in the pharmaceutical industry and finance. Currently, she is senior advisor, finance and a member of the executive committee at Innate Pharma, where she was responsible for a key licensing deal with Bristol-Myers Squibb. Previously, she was CFO at Movetis, where she played a major role in the company's IPO and subsequent acquisition by Shire. She also has held senior roles in investment banking at Morgan Stanley and Salomon Smith Barney.